Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Clonal Evolution × Lymphoid × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

blinatumomab 14 Cyclophosphamide 14 fludarabine 8 fludarabine phosphate 7 Methotrexate 7 Cytarabine 7 Vincristine 5 Rituximab 5 Mercaptopurine 5 Melphalan 4 Daunorubicin 4 obinutuzumab 3 Whole-Body Irradiation 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Doxorubicin 3 Dexamethasone 3 Asparaginase 3 tisagenlecleucel 2 thymoglobulin 2 pegaspargase 2 Vindesine 2 Thioguanine 2 Teniposide 2 Stem Cell Transplantation 2 Prednisone 2 Prednisolone 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Mycophenolic Acid 2 Immunotherapy, Adoptive 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡